Upon completion of the activity, participants will demonstrate improved competence and ability to:
For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:
For Clinical Practice:
Akshay S. Desai, MD, MPH, FHFSA
Medical Director, Cardiomyopathy and Heart Failure Program,
Advanced Heart Disease Section
Brigham and Women’s Hospital
Boston, MA
Jonathan Rich, MD, FHFSA
Associate Professor of Medicine
Northwestern University, Feinberg School of Medicine
Medical Director, Mechanical Circulatory Support Program
Program Director, Advanced Heart Failure and Transplant Fellowship
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
Chicago, IL
Nancy Sweitzer, MD, PhD, FHFSA
Professor of Medicine
Chief of Cardiology
Director, Sarver Heart Center
University of Arizona
Tucson, AZ
Heart Failure Fundamentals
Heart Failure Epidemiology and Risk Factors
Sadiya Khan
Pathophysiology I: Cellular and Energetic Considerations
Daniel Burkhoff
Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations
Diagnosis and Clinical Assessment
Mark Drazner
Device Therapy in Heart Failure
Liviu Klein
Cardio-Oncology for the HF boards
Anju Nohria
Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards
Jon Lomasney
Welcome & HFSA Introduction – Day 1
Welcome & HFSA Introduction
Akshay Desai, John Barnes
Cardiac Transplantation
Moderator: Nancy Sweitzer
Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies
Nancy Sweitzer
Immunology: The Basics, PRA, Sensitization, Crossmatch
Sean Pinney
Rejection: Cellular and Antibody Mediated
Managing Immunosuppression and Drugs
Michelle Kittleson
Heart Transplant, Clinical Outcomes and Complications
Key Issues in HF Management
Moderator: Jonathan Rich
Hemodynamics in HF I
James Fang
Hemodynamics in HF II
Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)
Clyde Yancy
Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)
HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)
Sanjiv Shah
Management of the Hospitalized HF Patient
Meredith Brisco-Bacik
Management of Common Arrhythmias in HF (including AF)
Management of Comorbidities in Heart Failure
Specific Heart Failure Syndromes
Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)
Akshay Desai
Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)
Jane Wilcox
Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)
Q&A Panel I
Q&A ---- Overview
Akshay Desai, Nancy Sweitzer, Jonathan Rich
Welcome & HFSA Introduction – Day 2
Shock/MCS
Cardiogenic Shock Management
MCS I: Durable MCS Devices and Outcomes
Joseph Rogers
MCS II: Temporary Support Devices and ECMO for the Boards
Jennifer Cowger
MCS III: MCS Complications and Patient Management
MCS IV: Troubleshooting (with HARVI)
Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer
Special Topics in HF
Moderator: Akshay Desai
Assessment of Functional Capacity including cardiopulmonary exercise testing
Gregory Lewis
Adult Congenital Heart Disease for the HF Specialist
Eric Krieger
Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)
Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)
Pulmonary Hypertension
Jonathan Rich
Q&A Panel II
Meredith Brisco-Bacik, MD, MSCE
Director, Heart Failure Clinical Research
Advanced Heart Failure and Cardiac Transplantation
The Lewis Katz School of Medicine at Temple University
Philadelphia, PA
Daniel Burkhoff, MD, PhD
Columbia University
New York, NY
Jennifer Cowger, MD, MS
Medical Director of Mechanical Circulatory Support Program
Co-Director of the Cardiac Intensive Care Unit
Henry Ford Hospitals, Detroit Michigan
Associate Professor, Wayne State University
Detroit, MI
Mark Drazner, MD, MSc, FHFSA
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program Professor
University of Texas Southwestern Medical Center
Dallas, TX
James Fang, MD, FHFSA
Chief, Division of Cardiovascular Medicine
Executive Director, Cardiovascular Service Line
University of Utah
Salt Lake City, UT
Sadiya Khan, MD, MSc
Associate Professor of Medicine – Cardiology
Associate Professor of Preventive Medicine – Epidemiology
Northwestern University Feinberg School of Medicine
Michelle Kittleson, MD, PHD
Director of Post Graduate Medical Education in Heart Failure and Transplantation
Director of Heart Failure Research
Cedars Sinai Medical Center
Beverly Hills, CA
Liviu Klein, MD, MS
Division of Cardiology, University of California San Francisco
Director, Cardiology Clinical Research
Director, Mechanical Circulatory Support & Heart Failure Device Program
University of California, San Francisco
San Francisco, CA
Eric Krieger, MD
Director, Seattle Adult Congenital Heart Service
Director, Adult Congenital Heart Disease Fellowship
Attending Physician, University of Washington Medical Center
University of Washington School of Medicine
Seattle Children’s Hospital
Seattle, WA
Gregory Lewis, MD
Section Head, Heart Failure
Director, Cardiopulmonary Exercise Testing Laboratory
Medical Director, Cardiac Transplantation Program
Massachusetts General Hospital
Jon Lomasney, MD
Associate Professor of Pathology
Associate Professor of Pharmacology
Feinberg School of Medicine of Northwestern University
Anju Nohria, MD, MSc
Associate Physician, Brigham and Women’s Hospital
Assistant Professor of Medicine, Harvard Medical School
Sean Pinney, MD
Director, Advanced Heart Failure and Transplantation Program
The Mount Sinai Hospital
Joseph Rogers, MD
Chief Medical Officer
Duke University Health System
Professor of Medicine – Cardiology
Duke University
Durham, NC
Sanjiv Shah, MD
Stone Professor of Medicine
Director of Research, Bluhm Cardiovascular Institute
Director, Northwestern HFpEF Program
Division of Cardiology, Department of Medicine
Jane Wilcox, MD, MSc, FHFSA
Assistant Professor of Medicine
Director, Myocardial Recovery Program
Associate Director, T1 Center for
Cardiovascular Therapeutics
Bluhm Cardiovascular Institute
Clyde W. Yancy, MD, MSc, FHFSA
Vice-Dean, Diversity & Inclusion
Professor, Medical Social Sciences
Associate Director
Deputy Editor, JAMA Cardiology
Credit Designation
This HFSA Board Review Certification Course has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.
These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.
Physicians
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Heart Failure Society of America designates this live activity for a maximum of 19 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the post course evaluation with a passing score of 80% on the posttests, enables the participant to earn up to 19 MOC points in the Maintenance of Certification (MOC) program. Participants of the live virtual activity wishing to claim MOC must complete requirements no later than Monday, November 23, 2020. This will allow time for the HFSA, the CME provider, to submit the participant’s completion information to ACCME for the purpose of granting ABIM MOC credit.
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
OFF-LABEL DISCLOSURE
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year’s HFSA Virtual Board Certification Review Course:
AbbottAmgenAstraZeneca
Medtronic Merck
Relypsa